NYSE · Healthcare
AbbVie Inc. (ABBV)
As-reported financials and recent SEC filings for AbbVie Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$61.16B
Net income
$4.23B
Net margin
6.9%
Diluted EPS
$2.36
ROE
-130.9%
P/E (TTM)
111.1×
Market cap
$402.35B
Debt / equity
-18.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Gross profit | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| Diluted EPS | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SD2026-06-01
View on EDGAR →1442026-05-26
View on EDGAR →42026-05-12
View on EDGAR →42026-05-12
View on EDGAR →42026-05-12
View on EDGAR →42026-05-12
View on EDGAR →42026-05-12
View on EDGAR →42026-05-12
View on EDGAR →Go deeper on ABBV
Search AbbVie Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.